THX Pharma Société Anonyme (FRA:3VG)

Market Cap	48.01M +1,113.4%
Revenue (ttm)	876.13K -61.3%
Net Income	-2.94M
EPS	-0.31
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	460
Average Volume	472
Open	3.360
Previous Close	3.580
Day's Range	3.360 - 3.530
52-Week Range	0.365 - 4.310
Beta	n/a
RSI	61.54
Earnings Date	Apr 28, 2026

About FRA:3VG

THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pharma Société Anonyme in September 2025. The company was founded in 2013 and is headquartered in Lyon, France.

• Industry: Pharmaceutical Preparations
• Founded: 2013
• Employees: 10
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 3VG

Financial Performance

In 2024, FRA:3VG's revenue was 2.28 million, an increase of 670.55% compared to the previous year's 296,331. Losses were -1.77 million, -74.15% less than in 2023.